OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Apple - Do you know I'm tired of reading about your desire for the OXB sp to drop so you can buy, only to sell when it's inched up a penny or two. We all know you do this so do us all a favour and don't labour the fact all the time.

queen1 Do you think this thread has any real affect on the SP. Let him/her practice their keyboard skills.

Well then queen1, if you are tired then have a sleep.

If reading this bores you to sleep then I'm glad that I could help.

Fred1new - no, I don't think the thread has any affect at all it just seems as though the apple record is stuck and needs changing.

apple - I wouldn't have an issue if you weren't always so smug about the whole thing. Still, it must be nice to be right all the time. Bless you.

queen1 I think you had a holding in BRW a while ago and got out with profit. Price dropped back to <=100 but had good results 1/6/05 price going up. Unfortunately did not sell at 140p but expect or see it again within 3-4/12. now about 105 Dyoh

Good memory Fred1new! I have been monitoring BRW and may look again if strength through 130p persists. Best of luck to you with your current holding.

anybody got a reason why the heavy downside today???

Yeh - down 7% and currently with more "recorded" buyers than sellers. Anyone have an educated view?

June is not the month to have an educated view so I'll demonstrate my ignorance. Presumably MMs will squeeze the sp to get rid of weak holders in the light of the recent strong sp performance. Until there is further announcements expect the sp to oscillate quite wildly.

That as usual sounds quite educated to me "pachandl" thanks.

:-)

Oxford Biomedica, Viragen, Roslin Institute develop anticancer antibody in eggs
AFX


LONDON (AFX) - Oxford Biomedica PLC, gene therapy company Viragen Inc and the Roslin Institute (Scotland) said they have made a breakthrough in their collaborative project for Avian Transgenic Biomanufacturing and have developed an anticancer antibody in chicken eggs.

For the first time, the collaboration has produced a potentially therapeutic protein selectively in the whites of eggs laid by a transgenic hen.

This technology is expected to offer a low cost manufacturing alternative for the production of many protein drugs, with additional potential advantages in the quality of the products, Oxford said.



newsdesk@afxnews.com

slm/

sounds good to me, its a shame this news didnt come before the drop during the week other wise we could be at the dizzy heights of 35+

www.myan.de/article119916.html

Friday news about OXB:

http://www.pharmalive.com/News/index.cfm?articleid=245336&categoryid=40


http://news.scotsman.com/latest.cfm?id=4642498


http://www.biomedicalproducts.com/ShowPR~PUBCODE~090~ACCT~9000000100~ISSUE~0506~RELTYPE~RLSN~PRODCODE~00000000~PRODLETT~C.html


http://www.thisismoney.co.uk/investing-and-markets/article.html?in_article_id=401067&in_page_id=3


http://southflorida.bizjournals.com/southflorida/stories/2005/05/30/daily45.html


http://abcnews.go.com/Health/wireStory?id=816471

Courtesy of qpr (ADV)
Saturday:
From todays Times :
Positive data on the use of Innurex, its gene-based therapy for nerve regeneration, on spinal cord injury helped Oxford Biomedica up 2p to 31p


From todays Financial Times :
Oxford BioMedica rose 8.7 per cent to 31p as the gene therapy company presented encouraging data on its product for nerve repair in spinal cord injuries to the American Society of Gene Therapy meeting in St Louis, Missouri. There was also talk it could announce a licencing deal with Pfizer, the worlds largest pharmaceutical group, for another of its products next week.

From todays Independent :
Oxford BioMedica rose 2.5p to 31.25p on the back of positive trial results from one of its technologies. The stock was also boosted by suggestions the company is on the way to securing a licensing agreement for one of its products with a US pharmaceuticals giant.

On the basis of those reports - me thinks I will start taking the Independent

Nicked from other BBs!

http://www.medicalnewstoday.com/medicalnews.php?newsid=25623

http://maconareaonline.com/news.asp?id=11006

http://news.bbc.co.uk/1/hi/scotland/4607653.stm

http://www.axcessnews.com/health_060405b.shtml

Fin. Mail: "Pfizer deal poised to lift Biomedica shares"

From yesterdays FT.
Oxford BioMedica rose 8.7 per cent to 31p as the gene therapy company presented encouraging data on its product for nerve repair in spinal cord injuries to the American Society of Gene Therapy meeting in St Louis, Missouri. There was also talk it could announce a licencing deal with Pfizer, the world's largest pharmaceutical group, for another of its products next week.

RNS Number:1523N Oxford Biomedica PLC 06 June 2005


FOR IMMEDIATE RELEASE 6 JUNE 2005



OXFORD BIOMEDICA SIGNS LENTIVECTOR(R) LICENSING AGREEMENT WITH PFIZER


Oxford, UK: 6 June 2005 - Oxford BioMedica (LSE: OXB), the leading gene therapy company, announced today that it has signed a licence agreement for its LentiVector technology with Pfizer (NYSE: PFE). The agreement provides Pfizer with use of the Company's proprietary LentiVector gene delivery system for research activities. Under the terms of the agreement, Oxford BioMedica will receive an upfront licence payment and an annual maintenance fee. Further financial details were not disclosed.

Oxford BioMedica's lentivirus-based gene delivery technology, known as LentiVector, is one of the most powerful technologies for the delivery of genes to a wide range of cell and tissue types. The LentiVector technology has applications both in therapeutic products and as a drug discovery tool for target validation and the creation of targeted disease models. It has also been shown to enhance the efficiency of making transgenic birds and mammals. Oxford BioMedica has a comprehensive portfolio of US and European patents that cover the LentiVector technology.

Commenting on the news Oxford BioMedica's Senior Vice President Commercial Development, Peter Nolan, said: "We are delighted to add Pfizer to our list of licensees for the LentiVector technology The versatility and safety of lentiviral vectors make them the system of choice for gene target validation in the drug discovery process as well as for the direct therapeutic applications in neurotherapy that Oxford BioMedica is pursuing. An increasing number of companies are using the LentiVector technology and we expect to establish a number of new partnerships around the technology".


Ends-

Coutesy of Gerry on Adv.

Links to today's News :-

http://biz.yahoo.com/iw/050606/088126.html

http://www.sharecast.com/cgi-bin/sharecast/story.cgi?story_id=490112

http://www.marketwire.com/mw/release_html_b1?release_id=88126